<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432913</url>
  </required_header>
  <id_info>
    <org_study_id>EPA/POL/02</org_study_id>
    <nct_id>NCT00432913</nct_id>
  </id_info>
  <brief_title>Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa</brief_title>
  <official_title>The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S.L.A. Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S.L.A. Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of two doses purified EPA (an omega-3
      fatty acid), on apoptosis (natural cell death) and cell proliferation (formation of new
      cells) in the lining of the colon for patients with a history of colonic polyps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is generally accepted to develop from changes within colonic adenomatous
      polyps. More than 90% of new large bowel cancers arise sporadically. The molecular events
      leading to the development of colorectal cancer from polyps are characterised by an imbalance
      in cell proliferation (formation of new cells) and apoptosis (natural cell death) from
      changes in the genes involved in normal colon cells.

      Recent work at St George's Hospital Medical School, London, has shown significant beneficial
      effects on cell proliferation and apoptosis rates in the lining of the colon in subjects with
      a history of colonic adenomas using a highly purified, free-fatty acid form of
      eicosapentaenoic acid (EPA).

      Comparator(s): 2g EPA per day for 6 months and 1g EPA per day for 6 months will be compared
      against placebo for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure levels of apoptosis in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure levels of cell proliferation in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the tissue content of EPA in the colonic mucosa before, during and after treatment with EPA.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of EPA.</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adenomatous Polyps</condition>
  <arm_group>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic Acid (EPA)</intervention_name>
    <description>Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <other_name>ALFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
    <description>At baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Colonoscopy</other_name>
    <other_name>Flexible sigmoidoscopy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies taken</intervention_name>
    <description>9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical chemistry</intervention_name>
    <description>Full blood count at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haematology</intervention_name>
    <description>Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical examination</intervention_name>
    <description>Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vital signs</intervention_name>
    <description>Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine pregnancy test</intervention_name>
    <description>For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Completion of patient diary card</intervention_name>
    <description>Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.</description>
    <arm_group_label>1g EPA per day</arm_group_label>
    <arm_group_label>2g EPA per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged over 18

          -  Patients of child-bearing potential must demonstrate a negative pregnancy test at
             screening, and should use a reliable form of contraception during the trial and for 1
             month afterwards, e.g:

          -  Oral contraceptive + condom

          -  Intra-uterine device (IUD)+ condom

          -  Diaphragm with spermicide + condom

          -  Male partners of women of child bearing potential should use a reliable form of
             contraception during the trial and for 1 month afterwards, e.g:

          -  Oral contraceptive + condom

          -  Intra-uterine device (IUD)+ condom

          -  Diaphragm with spermicide + condom

          -  Patients must have a known history of colorectal adenomata and be under clinical
             follow-up for these, or be found to have one or more of these at the time of
             colonoscopy

          -  Patients must have provided written informed consent to participate

        Exclusion Criteria:

          -  Patients who are allergic to fish

          -  Patients who have diabetes mellitus

          -  Patients who are pregnant or breast-feeding

          -  Patients taking aspirin or other non-steroidal anti-inflammatory drugs on a regular
             basis

          -  Patients who have aspirin-sensitive asthma

          -  Patients suffering from haemorrhagic disorders

          -  Patients who are taking warfarin or other anticoagulants

          -  Patients who have significant abnormalities on their screening blood tests

          -  Patients taking lipid lowering medication

          -  Patients with known inflammatory bowel disease (IBD), or previously unknown IBD until
             discovered at the time of their colonoscopy

          -  Patients with gastrointestinal malabsorptive disease

          -  Patients belonging to a known polyposis syndrome (e.g. FAP, HNPCC)

          -  Patients with a previous colonic resection for colorectal cancer

          -  Patients who are taking other fish-oil supplements (e.g. cod liver oil) who are
             unwilling to stop them for the duration of the study

          -  Patients who are deemed mentally incompetent, or have a history of anorexia nervosa or
             bulimia

          -  Patients with a history of alcohol or drug abuse, including laxative abuse

          -  Patients considered by their physician unlikely to be able to comply with the
             protocol.

          -  Patients who have taken part in an experimental drug study in the preceding 2 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J West, MB BS FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. George's Hospital Medical School, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S. Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital Medical School</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <keyword>Eicosapentaenoic acid</keyword>
  <keyword>EPA</keyword>
  <keyword>EPA 99%</keyword>
  <keyword>Fatty acid</keyword>
  <keyword>omega-3</keyword>
  <keyword>apoptosis</keyword>
  <keyword>cell proliferation</keyword>
  <keyword>colonic mucosa</keyword>
  <keyword>polyps</keyword>
  <keyword>adenomatous polyps</keyword>
  <keyword>endoscopy</keyword>
  <keyword>PUFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

